Merck's ENFLONSIA Approval Just Reframed the Post-Keytruda Pipeline Story

Understand the concentration problem first. Keytruda crossed $25 billion in 2023 and is on track for $30-32 billion in 2026. That single product represents roughly 45-48% of Merck's pharmaceutical segment revenue. No other franchise above $6 billion sits on the income statement. The loss-of-exclusivity timeline is well-publicised: biosimilars begin US entry from 2028, with peak erosion expected in the 2029-2031 window.

The consensus 2031 revenue walk has been ugly. Sell-side models embed a $10-12 billion Keytruda erosion over three years, absorbed against launches of Capvaxive (pneumococcal), Winrevair (pulmonary arterial hypertension), clesrovimab, the Moderna personalised cancer vaccine partnership, and a TIGIT-based combination therapy stack. Each launch is probabilistic on its own. The question is whether the aggregate launch slate can offset the erosion.

The ENFLONSIA approval moves one of those launches from probability to commercial reality. The RSV infant prevention market is a two-player market after this approval. Beyfortus (the Sanofi-AstraZeneca molecule) is currently the only product with broad distribution. Clesrovimab enters with a single-dose convenience edge and a pricing flexibility that Beyfortus does not offer. Early uptake data from the US (where FDA approved in mid-2025) has shown clesrovimab capturing roughly 18-22% of first-season prescriptions. On a $3-4 billion total addressable RSV infant prevention market at maturity, a 25-30% share translates to $900 million to $1.2 billion of peak revenue. Not enormous against the Keytruda gap, but important because it validates the pattern.

Before ENFLONSIA's EU approval, the sell-side distribution on 2031 Merck revenue ran from $54 billion at the bearish end to $68 billion at the bullish end. The mode sat around $60 billion. The distribution was wide because each launch in the backfill slate carried its own commercial risk, and the aggregate weighted probability of hitting a $65 billion-plus number looked slim.

With clesrovimab de-risked in Europe, one of the six major backfill launches has gone from probabilistic to confirmed commercial in the two largest prescription markets in the world. That shifts the distribution. Sell-side 2031 revenue consensus should drift from $60 billion toward $62-63 billion, with the standard deviation tightening slightly. More importantly, the correlation structure across pipeline assets has shifted: investors now have evidence that Merck's commercial launch machinery can execute in a two-player category with a differentiated competitor (Beyfortus). That read-through matters for Capvaxive's positioning against Prevnar, and for Winrevair's positioning in a market that is attracting competition.

This pattern is worth watching. When pharmaceutical majors begin to execute on pipeline diversification after a major loss-of-exclusivity event becomes visible on the horizon, the market tends to re-rate in two steps: first when the aggregate approval count reaches three significant launches, and second when the aggregate revenue from backfill products crosses an identifiable share of the LOE-exposed revenue. Merck is now at approval count one of the first phase. The ENFLONSIA milestone is a pattern confirmation, not a pattern completion.

Historically, the analogous setup in large-cap pharma has been Pfizer's 2011-2014 walk through Lipitor's loss-of-exclusivity. The backfill narrative took four approvals and three years to translate into a multiple re-rate. Merck's pipeline is denser than Pfizer's was at the analogous point, and the Keytruda cliff lands with more runway. The base case is a re-rate over the 2027-2029 window rather than an immediate catalyst move.

Zoom in on the RSV infant prevention market for a minute, because its structure tells you how Merck is likely to execute across the broader backfill slate. Beyfortus arrived in 2023 and captured an effectively empty market. Clesrovimab arrived in 2025 in the US and mid-2026 in Europe, and immediately took 18-22% share in the first US season despite a cold-chain logistical disadvantage and a narrower clinical label in some indications.

Why did clesrovimab capture share at all? Because the payer landscape for RSV infant prevention rewards a second option. Sanofi-AstraZeneca priced Beyfortus aggressively in year one; clesrovimab's single-dose positioning and supply-chain configuration gave payers leverage to negotiate. The two-player dynamic lowered average net pricing by roughly 8-12% but expanded addressable market penetration by a larger factor. Peak market value at maturity is therefore higher with two players than it would have been with one, and Merck's clesrovimab captures the marginal share.

The read-through to Capvaxive (which competes against Prevnar in pneumococcal) and to the TIGIT combinations (which compete against the emerging multi-combination immuno-oncology stack) is that Merck's competitive execution appears capable of operating effectively in markets it does not dominate. That is not the same operating posture the company held during the Keytruda monopoly years. It is a healthier, more competitive posture that the market has not yet priced.

The data points to watch from here: Capvaxive US uptake share by Q4 2026; the Keytruda subcutaneous conversion trajectory as biosimilar entry approaches; the TIGIT clinical readouts through 2027. Three clean data points across three different mechanisms would move the 2031 revenue distribution meaningfully.

Break the backfill problem into its components. Capvaxive is Merck's adult pneumococcal vaccine, launched in 2024 and expanding label. It competes against Pfizer's Prevnar franchise in a market that is already $10+ billion. A reasonable uptake assumption gets Capvaxive to $2.5-3.5 billion of peak revenue by 2031. Winrevair targets pulmonary arterial hypertension, a rare-disease category where Merck's acquisition of Acceleron originated the asset. Peak revenue projections run from $3 billion at the low end to $5.5 billion at the bullish end. Clesrovimab we have already discussed; $900M-$1.2B peak.

The Keytruda subcutaneous conversion is the most interesting single asset in the portfolio. If the sub-q formulation receives approval and achieves the kind of conversion uptake that AstraZeneca has demonstrated with Phesgo, roughly 25-30% of Keytruda's IV volume migrates to the sub-q formulation before biosimilar entry. That matters because sub-q Keytruda is protected by a separate patent stack and therefore partially insulated from biosimilar erosion in the 2028-2031 window. Peak sub-q revenue could reach $8-10 billion, meaningfully mitigating the net Keytruda gap.

The TIGIT combination programs are the most speculative component of the stack. Read-outs through 2027 will determine whether TIGIT combinations produce a commercially meaningful additional indication for Keytruda-anchored regimens. A positive readout on the NSCLC combination alone is worth $2-3 billion of peak revenue. A negative readout eliminates that contribution entirely. This is a true binary.

Finally, the Moderna personalised cancer vaccine partnership. The economics here are split, and the peak revenue potential for Merck's share is uncertain. A conservative model adds $1-2 billion. A bullish model adds $4-5 billion. The Phase 3 data through 2027 will determine the range.

Run two scenarios on Merck's 2031 earnings power. Scenario A assumes the backfill pipeline captures 70% of the Keytruda erosion, with peak revenue in 2031 of $62 billion and operating margin normalising at 30%. That implies operating income of $18.6 billion, EPS of $6.50 and a 2031 P/E of 18x at today's share price. Scenario B assumes the backfill pipeline captures 90% of the erosion, with revenue at $66 billion and operating margin at 32%. That implies operating income of $21 billion, EPS of $7.80 and a 2031 P/E of 15x.

Both scenarios look reasonable against the current multiple. The question is which scenario the market ends up pricing as the central case. With ENFLONSIA approved, the probability weight on Scenario B has shifted up by perhaps 10-15 percentage points. That is not a dramatic move, but it is a move in the right direction, and it is the first such move in several quarters.

Time horizons matter for this trade. The 2031 pricing matters very little to a six-month holder. It matters a great deal to a two-to-three-year holder who can sit through the 2028-2029 biosimilar noise. The current dividend yield of 2.81% provides a carry that makes the patience trade workable. Each incremental approval (Capvaxive market expansion, subcutaneous Keytruda conversion, TIGIT readouts) compresses the bearish distribution and lifts the multiple slowly rather than in a single move. That is the drift pattern this name tends to follow.

The technical setup reinforces the point. The stock's 50-day moving average at $119 sits above the 200-day at $98 for the first time in thirteen months. The 52-week range of $71 to $124 captures the full bearishness and the initial optimism cycle; the stock now trades near the top of that range, implying the first phase of re-rating has begun. What the next phase needs is approval number two or three on the backfill slate.